EUVIMEDEUVIMED entdecken
Fallbericht

Mosaic RASopathy Caused by a Somatic HRAS p. Gly12Ser Variant in a Patient With Malignant Melanoma

Chihiro Sagara, Yan Yihan, Daiki Rokunohe iD, Akari Terada, Eijiro Akasaka iD

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.70421 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Chihiro Sagara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Melanoma, Skin Neoplasms, Keratoderma, Palmoplantar. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postzygotic somatic variants affecting the Ras/MAPK signaling pathway can cause mosaic RASopathies, characterized by craniofacial abnormalities, cardiac defects, growth impairment, and various cutaneous manifestations in localized areas of the body. Herein, we present a rare case of mosaic RASopathy caused by a somatic HRAS variant. A 52‐year‐old Japanese patient visited our department because of skin metastasis of malignant melanoma. Besides, he had a sebaceous nevus on the forehead, linear epidermal nevus on the trunk along with the Blaschko line, and focal and linear non‐epidermolytic palmoplantar keratoderma since he was young. Genetic testing revealed an HRAS missense variant c.34G>A (p.Gly12Ser) in the cells of sebaceous nevus, pigmented skin lesion, palmoplantar keratoderma, and metastatic skin lesion of melanoma. In contrast, no pathogenic HRAS variant was detected in peripheral blood leukocytes or in clinically normal skin. Somatic mutations in HRAS can cause mosaic Costello syndrome, Schimmelpenning syndrome, and woolly hair nevus. However, there is some overlap in clinical manifestations among these diseases, and no clear diagnostic criteria have been established. Therefore, we diagnosed this case as HRA S‐mutant mosaic RASopathy. In addition, this is the first reported case of mosaic RASopathy concomitant with malignant melanoma. Although the occurrence of concurrent melanoma would be coincidental in this case, further investigation is necessary to evaluate the precise association between HRAS ‐mutant mosaic RASopathy and melanoma. The melanoma cells showed a high proportion of mutant alleles, possibly due to loss of heterozygosity. Further investigation is necessary to evaluate the precise association between HRAS ‐mutant mosaic RASopathy and melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)MelanomaSkin NeoplasmsKeratoderma, PalmoplantarNevus, Sebaceous of JadassohnHumansMiddle AgedMaleMosaicismMutation, MissenseSkinCutaneous Malignant Melanoma

Stichwörter der Autor:innen

HRASRASopathymelanomamosaicp.Gly12Sersebaceous nevus

Substanzen

Proto-Oncogene Proteins p21(ras)HRAS protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

ORCID-Profile: Daiki Rokunohe, Eijiro Akasaka

Zitieren

APA

Sagara, C., Yihan, Y., Rokunohe, D., Terada, A., & Akasaka, E. (2026). Mosaic RASopathy Caused by a Somatic HRAS p. Gly12Ser Variant in a Patient With Malignant Melanoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70421

Vancouver

Sagara C, Yihan Y, Rokunohe D, Terada A, Akasaka E. Mosaic RASopathy Caused by a Somatic HRAS p. Gly12Ser Variant in a Patient With Malignant Melanoma. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70421

BibTeX
@article{Sagara2026,
  author = {Sagara, Chihiro and Yihan, Yan and Rokunohe, Daiki and Terada, Akari and Akasaka, Eijiro},
  title = {Mosaic RASopathy Caused by a Somatic HRAS p. Gly12Ser Variant in a Patient With Malignant Melanoma},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.70421}
}
Kostenlos starten →